Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma

Published:2024-05-03 Issue:5 Volume:24 Page:339-350
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Jagannath Sundar¹^ORCID,Jackson Carolyn C.²,Schecter Jordan M.²,Lendvai Nikoletta²,Sun Huabin²,Akram Muhammad³,Patel Nitin³,Martin Thomas G.⁴

Affiliation:

1. Multiple Myeloma Division, Tisch Cancer Institute, Mount Sinai Medical Center New York, New York, NY, USA

2. Janssen Research & Development, Raritan, NJ, USA

3. Legend Biotech USA Inc, Somerset, NJ, USA

4. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

Funder

Janssen Global Services, LLC

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2024.2352591

Reference77 articles.

1. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

2. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

5. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?;Hemato;2024-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3